Operating Income (Loss) of Y-mAbs Therapeutics, Inc. from 31 Mar 2017 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Y-mAbs Therapeutics, Inc. quarterly and annual Operating Income (Loss) in USD history and change rate from 31 Mar 2017 to 30 Jun 2025.
  • Y-mAbs Therapeutics, Inc. Operating Income (Loss) for the quarter ending 30 Jun 2025 was $5,604,000, a 43% increase year-over-year.
  • Y-mAbs Therapeutics, Inc. Operating Income (Loss) for the twelve months ending 30 Jun 2025 was $26,651,000, a 3.6% increase year-over-year.
  • Y-mAbs Therapeutics, Inc. annual Operating Income (Loss) for 2024 was $31,201,000, a 22% decline from 2023.
  • Y-mAbs Therapeutics, Inc. annual Operating Income (Loss) for 2023 was $25,672,000, a 73% increase from 2022.
  • Y-mAbs Therapeutics, Inc. annual Operating Income (Loss) for 2022 was $94,811,000, a 18% increase from 2021.
Source SEC data
View on sec.gov
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Y-mAbs Therapeutics, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $26,651,000 $5,604,000 +$4,185,000 +43% 01 Apr 2025 30 Jun 2025 10-Q 08 Aug 2025 2025 Q2
Q1 2025 $30,836,000 $6,543,000 +$365,000 +5.3% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $31,201,000 $5,936,000 -$2,737,000 -86% 01 Oct 2024 31 Dec 2024 10-K 04 Mar 2025 2024 FY
Q3 2024 $28,464,000 $8,568,000 -$819,000 -11% 01 Jul 2024 30 Sep 2024 10-Q 08 Nov 2024 2024 Q3
Q2 2024 $27,645,000 $9,789,000 -$2,566,000 -36% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2025 2025 Q2
Q1 2024 $25,079,000 $6,908,000 +$593,000 +7.9% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $25,672,000 $3,199,000 -$2,045,000 -177% 01 Oct 2023 31 Dec 2023 10-K 04 Mar 2025 2024 FY
Q3 2023 $23,627,000 $7,749,000 +$18,268,000 +70% 01 Jul 2023 30 Sep 2023 10-Q 08 Nov 2024 2024 Q3
Q2 2023 $41,895,000 $7,223,000 +$32,722,000 +82% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $74,617,000 $7,501,000 +$20,194,000 +73% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $94,811,000 $1,154,000 +$34,604,000 +97% 01 Oct 2022 31 Dec 2022 10-K 29 Feb 2024 2023 FY
Q3 2022 $129,415,000 $26,017,000 +$2,687,000 +9.4% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $132,102,000 $39,945,000 -$17,233,000 -76% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $114,869,000 $27,695,000 +$564,000 +2% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q4 2021 $115,433,000 $35,758,000 -$15,663,000 -78% 01 Oct 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
Q3 2021 $99,770,000 $28,704,000 +$3,937,000 +12% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022 2022 Q3
Q2 2021 $103,707,000 $22,712,000 +$17,740,000 +44% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2021 Q3
Q1 2021 $121,447,000 $28,259,000 -$1,512,000 -5.7% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $119,935,000 $20,095,000 +$3,663,000 +15% 01 Oct 2020 31 Dec 2020 10-K 01 Mar 2021 2020 FY
Q3 2020 $123,598,000 $32,641,000 -$8,282,000 -34% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $115,316,000 $40,452,000 -$21,818,000 -117% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $93,498,000 $26,747,000 -$10,494,000 -65% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $83,004,000 $23,758,000 -$9,680,000 -69% 01 Oct 2019 31 Dec 2019 10-K 01 Mar 2021 2020 FY
Q3 2019 $73,324,000 $24,359,000 -$12,944,000 -113% 01 Jul 2019 30 Sep 2019 10-K 01 Mar 2021 2020 FY
Q2 2019 $60,380,000 $18,634,000 -$8,376,000 -82% 01 Apr 2019 30 Jun 2019 10-K 01 Mar 2021 2020 FY
Q1 2019 $52,004,000 $16,253,000 -$8,774,000 -117% 01 Jan 2019 31 Mar 2019 10-K 01 Mar 2021 2020 FY
Q4 2018 $43,230,000 $14,078,000 -$4,803,000 -52% 01 Oct 2018 31 Dec 2018 10-K 12 Mar 2020 2019 FY
Q3 2018 $38,427,000 $11,415,000 -$7,573,000 -197% 01 Jul 2018 30 Sep 2018 10-K 12 Mar 2020 2019 FY
Q2 2018 $30,854,000 $10,258,000 -$7,028,000 -218% 01 Apr 2018 30 Jun 2018 10-K 12 Mar 2020 2019 FY
Q1 2018 $23,826,000 $7,479,000 -$4,582,000 -158% 01 Jan 2018 31 Mar 2018 10-K 12 Mar 2020 2019 FY
Q4 2017 $19,244,000 $9,275,000 01 Oct 2017 31 Dec 2017 10-K 22 Mar 2019 2018 FY
Q3 2017 $3,842,000 01 Jul 2017 30 Sep 2017 10-K 22 Mar 2019 2018 FY
Q2 2017 $3,230,000 01 Apr 2017 30 Jun 2017 10-K 22 Mar 2019 2018 FY
Q1 2017 $2,897,000 01 Jan 2017 31 Mar 2017 10-K 22 Mar 2019 2018 FY

Y-mAbs Therapeutics, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $31,201,000 -$5,529,000 -22% 01 Jan 2024 31 Dec 2024 10-K 04 Mar 2025 2024 FY
2023 $25,672,000 +$69,139,000 +73% 01 Jan 2023 31 Dec 2023 10-K 04 Mar 2025 2024 FY
2022 $94,811,000 +$20,622,000 +18% 01 Jan 2022 31 Dec 2022 10-K 29 Feb 2024 2023 FY
2021 $115,433,000 +$4,502,000 +3.8% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
2020 $119,935,000 -$36,931,000 -44% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2022 2021 FY
2019 $83,004,000 -$39,774,000 -92% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
2018 $43,230,000 -$23,986,000 -125% 01 Jan 2018 31 Dec 2018 10-K 12 Mar 2020 2019 FY
2017 $19,244,000 01 Jan 2017 31 Dec 2017 10-K 22 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.